Please login to the form below

Not currently logged in
Email:
Password:

Celerion appoints chief medical officer

Dr Marc Hoffman brings experience from Patient IP and Theorem Clinical Research

Celerion Dr Marc HoffmanClinical research and pharmacology service provider Celerion has appointed Dr Marc Hoffman as chief medical officer.

Dr Hoffman joins Celerion from Patient Identification Platform, where he also served as chief medical officer, overseeing the firm's platform and programmes.

He brings further experience from Theorem Clinical Research, where he was chief medical officer, senior vice president and general manager.

Previously, Dr Hoffman served as vice president of medical and scientific affairs at Covance and vice president of global medical affairs and product safety at Hospira.

He also brings experience as vice president for global regulatory affairs and medical vigilance for Baxter's operations in Asia and the Americas.

Dr Susan Thornton, president and chief executive officer of Celerion, said: “We are pleased to have Marc join our executive leadership team during this exciting period of growth in our company.

“His depth of experience in managing all aspects of global drug development in multiple therapeutic areas will not only make him a valuable asset for our organization but also for our clients.”

27th February 2017

From: Research

Share

Tags

PMEA Awards 2020

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Say Communications

Influencing positive behaviours and delivering change is what drives us, using thought leadership, education, social and professional engagement and compelling,...

Latest intelligence

EU health fund
An EU emergency health fund to limit the impact of future crises
Leading finance experts propose an Emergency Health Financing Facility to limit the impact of future crises on the EU...
Mistrust in medical research: a patient perspective
The recent development of several COVID-19 vaccines has placed medical research firmly in the spotlight, highlighting public confusion and misinformation about clinical trials. Patient advocate, Trishna Bharadia reveals what the...
Real-world evidence: breaking boundaries in rare disease
Generating data for drug launches is a challenging process. In rare diseases, with small patient populations and high unmet need, evidence generation is even more complex. Consultant Sarah Poole and...

Infographics